QCG
IMVT icon

Quadrant Capital Group’s Immunovant IMVT Stock Holding History

Quadrant Capital Group’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-212
Closed -$5.27K – 1874
2026
Q1 		$5.27K Hold
212
– – ﹤0.01% 2342
2025
Q4 		$5.39K Buy
212
+132
+165% +$2.94K ﹤0.01% 2351
2025
Q3 		$1.29K Buy
+80
New +$1.29K ﹤0.01% 2535
2025
Q2 		– Sell
-515
Closed -$8.8K – 1946
2025
Q1 		$8.8K Buy
+515
New +$10.8K ﹤0.01% 2246
2021
Q4 		– Sell
-74
Closed -$1K – 2597
2021
Q3 		$1K Buy
+74
New +$668 ﹤0.01% 2322

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Quadrant Capital Group's IMVT Position: Q2 2026 in Review

Quadrant Capital Group sold out of Immunovant (IMVT) in Q2 2026, closing a stake of 212 shares — an estimated $5.27K sold.

Quadrant Capital Group first reported a position in IMVT in Q3 2021 and held it in 5 quarters. The position peaked at $8.8K in Q1 2025. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Quadrant Capital Group reported no remaining Immunovant position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 212 Immunovant shares in Q2 2026, an estimated $5.27K.
  • Quadrant Capital Group first reported a position in Immunovant in Q3 2021 and held it in 5 quarters.
  • Quadrant Capital Group's Immunovant position peaked at $8.8K in Q1 2025.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.